<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Thu, 19 Nov 2026 10:07:55 -0500--><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/">
    <channel>
        <title>ProMIS Neurosciences, Inc. (PMN) Press Releases</title>
        <link>https://www.promisneurosciences.com/news-media/press-releases/rss</link>
        <language>en-us</language>
        <description></description>

                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/promisneurosciences/files/theme/images/logo-sm.png</url>
                <title>ProMIS Neurosciences, Inc. Logo</title>
                <link>https://www.promisneurosciences.com</link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.promisneurosciences.com/news-media/press-releases/detail/280/promis-neurosciences-licenses-next-generation-txp1</link>
                <pubDate>Tue, 17 Nov 26 02:30:00 -0500</pubDate>
                <guid>https://www.promisneurosciences.com/news-media/press-releases/detail/280/promis-neurosciences-licenses-next-generation-txp1</guid>
                                                                                    <content:encoded><![CDATA[

<p align="center" style="text-align:center;"><em>TXP1 selectively increased antibody delivery to the brain by more than 65-fold in preclinical studies conducted by Ossianix</em></p>     <p align="center" style="text-align:center;"><em>License supports lifecycle management of the PMN310 franchise, with options to extend TXP1 to ProMIS’s Parkinson’s and ALS programs</em></p>     <p align="left" style="text-align:left;"><strong>Cambridge, Massachusetts, Nov.  17, 2026  (GLOBE NEWSWIRE) -- </strong>ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibodies that selectively target toxic misfolded proteins in neurodegenerative diseases, today announced that it has entered into a license agreement with Ossianix, Inc. for TXP1, a next-generation brain-selective shuttling technology targeting transferrin receptor 1 (TfR1). The agreement provides ProMIS rights to use TXP1 with PMN310, its lead antibody for Alzheimer’s disease (AD), and options to apply the technology to its Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) programs.</p>     <p align="left" style="text-align:left;">“This partnership is in support of the long-term value of our pipeline. Our ongoing efforts with PMN310 are unaffected by this agreement and we remain committed to advancing it as an intravenous (IV) and subcutaneous product, subject to upcoming data,” said Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences. “We believe TXP1 is among the most compelling TfR1 shuttles in development. Pairing it with antibodies that are selective for toxic misfolded proteins may provide a path to a second-generation PMN310 in AD with a more convenient subcutaneous dosing schedule and lower cost of goods and to next-generation candidates in our pipeline.”</p>     <p align="left" style="text-align:left;">TXP1 is built on a deimmunized, single-domain VNAR antibody scaffold that is significantly smaller than a conventional antibody. In preclinical studies reported by Ossianix, including studies in non-human primates, TXP1 increased delivery of a therapeutic antibody to the brain by more than 65-fold, with no accumulation observed in the liver, spleen, lung, kidney, bone marrow, heart or muscle. Ossianix has also reported a favorable PK profile with prolonged brain exposure, binding that does not compete with transferrin, and minimal impact on reticulocyte levels, an effect that has been reported with some TfR1-targeting approaches. Based on these preclinical data, ProMIS believes TXP1 has a differentiated profile among TfR1-based shuttles.</p>     <p align="left" style="text-align:left;">“We are proud to partner with ProMIS and see this agreement as strong validation of TXP1’s profile as a next-generation TfR1-targeting delivery technology,” said Frank Walsh, CEO of Ossianix. “By pairing our deimmunized VNAR platform—which binds a unique epitope—with ProMIS’s selective antibodies, we see a compelling opportunity to enable more convenient dosing across Alzheimer’s and expand into additional neurodegenerative programs.”</p>     <p align="left" style="text-align:left;">Under the terms of the agreement, Ossianix will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments, as well as royalties on global net sales. ProMIS also holds options to apply TXP1 to PMN442, its antibody targeting alpha-synuclein (implicated in Parkinson’s disease and dementia with Lewy bodies), and PMN267, its antibody targeting TDP-43 (implicated in ALS and frontotemporal dementia). ProMIS intends to fund its short-term obligations under the agreement from existing cash resources and does not expect the agreement to change its previously disclosed cash runway through 2027.</p>     <p align="left" style="text-align:left;">Destum Partners served as transaction advisor to Ossianix.</p>     <p align="left" style="text-align:left;"><strong>About ProMIS Neurosciences Inc.</strong></p>     <p align="left" style="text-align:left;">ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Parkinson’s disease (PD), and dementia with Lewy bodies (DLB). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).</p>     <p align="left" style="text-align:left;"><strong>About PMN310</strong></p>     <p align="left" style="text-align:left;">PMN310, the Company’s lead product candidate for the treatment of AD, is a humanized IgG1 monoclonal antibody designed to selectively target toxic oligomers while avoiding plaque, thereby potentially reducing or eliminating amyloid-related imaging abnormalities (ARIA) liability. PMN310 was granted Fast Track designation by the U.S. Food and Drug Administration in July 2025 and is being evaluated in PRECISE-AD (NCT06750432), a randomized, double-blind, placebo-controlled Phase 1b study in patients with mild cognitive impairment due to AD or mild AD.</p>     <p align="left" style="text-align:left;"><strong>About Ossianix, Inc.</strong></p>     <p align="left" style="text-align:left;">Ossianix is a privately held drug discovery and development company pioneering a new generation of brain-selective delivery technologies based on naturally occurring single-domain antibodies known as VNARs. Ossianix is headquartered in Philadelphia, Pennsylvania, with research laboratories in Stevenage, United Kingdom.</p>     <p align="left" style="text-align:left;"><strong>Forward-Looking Statements</strong></p>     <p align="left" style="text-align:left;">This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, “forward-looking information”) within the meaning of applicable securities laws. Statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Company’s license agreement with Ossianix; the potential of the TXP1 brain-selective shuttling technology to enhance brain delivery of the Company’s antibodies; the Company’s belief that TXP1 has a differentiated profile among TfR1-based shuttles; the potential development of a second-generation PMN310, including the potential for a more convenient dosing schedule and lower cost of goods; the Company’s plans to advance first-generation PMN310 as a subcutaneous product; the Company’s ability to exercise its options and apply TXP1 to its ALS and PD programs; the achievement of milestones and payment of royalties under the agreement; the Company’s expected cash runway; and the potential benefits of PMN310 and the Company’s pipeline candidates. Statements containing forward-looking information are not historical facts but instead represent management’s current expectations, estimates, and projections regarding the future of the business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions, and other factors that may cause actual results, level of activity, performance or achievement to differ materially from those expressed or implied, including, but not limited to, the risk that preclinical results, including results reported by Ossianix, may not be predictive of results in later studies or in humans, the risk that the licensed technology may not achieve its intended objectives, the risk that clinical data from the PRECISE-AD trial may be delayed or may not support further development or regulatory approval of PMN310, the Company’s accumulated deficit, and the expectation for continued losses. Important factors that could cause actual results to differ materially are discussed in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K and in its subsequent filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p>     <p align="left" style="text-align:left;"><strong>For Investor Relations, please contact:</strong></p>     <p align="left" style="text-align:left;"><strong>ProMIS Neurosciences Inc.</strong></p>     <p align="left" style="text-align:left;">Carie Pierce<br>VP, Investor Relations &amp; External Affairs<br><a href="https://www.globenewswire.com/Tracker?data=zA2N1os_pLnqMubnTFPnOi9wdSc5ugzS-cXRMTp_4hqlwrNbrXIkqyBOKeB8uNq01B0lxoIGVk-RD1OlIqRDyQSrsjTT_gAEzlo0WyU3YTYy_sp1qGjad_up7AzdY68d" rel="nofollow" target="_blank"><u>IR@promisneurosciences.com</u></a></p>     <p align="left" style="text-align:left;"><strong>Ossianix, Inc</strong><strong>.</strong></p>     <p align="left" style="text-align:left;">Dr. Steve Moore<br>COO, Ossianix, Inc.<br><a href="https://www.globenewswire.com/Tracker?data=9tBqAuqJJxGuarb4d_TirkL0l7ttKYIXt7b-NoURMAeJp6ar7_xc1U0o5jAfSefm2nop7r8jzt3XPRvPOvf0SXlbknIDCYMOb6PrX-szfxU=" rel="nofollow" target="_blank"><u>steve@ossianix.com</u></a></p>   <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/26bec3c9-ac4b-487b-ab90-3b62be29497d"><img src="https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg" border="0" width="150" height="63" alt="Primary Logo"></a></p>
Source: ProMIS Neurosciences Inc.

]]></content:encoded>
                            </item>
                    <item>
                <title><![CDATA[ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.promisneurosciences.com/news-media/press-releases/detail/279/promis-neurosciences-announces-third-quarter-2026-financial</link>
                <pubDate>Thu, 12 Nov 26 16:05:00 -0500</pubDate>
                <guid>https://www.promisneurosciences.com/news-media/press-releases/detail/279/promis-neurosciences-announces-third-quarter-2026-financial</guid>
                                                                                    <content:encoded><![CDATA[

<ul type="disc"><li><em>PRECISE-AD Phase 1b clinical trial in Alzheimer’s patients remains on track for unblinded 12-month topline data in the first quarter of 2027, including full safety, biomarker and cognitive outcomes data</em></li></ul>     <ul type="disc"><li><em>PMN310 binds selectively to toxic amyloid-beta oligomers, and its IgG1 backbone is designed to promote clearance of toxic oligomers</em></li></ul>     <ul type="disc"><li><em>Ivana Rubino, Ph.D., a seasoned Alzheimer’s commercial leader, appointed Chief Commercial Officer </em></li></ul>     <ul type="disc"><li><em>Cash of $44.1 million as of September 30, 2026, expected to fund operations through 2027, beyond the anticipated PRECISE-AD topline data readout</em></li></ul>     <p align="left" style="text-align:left;"><strong>Cambridge, Massachusetts, Nov.  12, 2026  (GLOBE NEWSWIRE) -- </strong>ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended September 30, 2026, and provided a corporate update.</p>     <p align="left" style="text-align:left;">“The third quarter of 2026 has been productive for ProMIS, following encouraging interim data from our Phase 1b PRECISE-AD trial in Alzheimer’s disease (AD),” said Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences. “Based on data generated to date, we continue to believe PMN310 offers a differentiated approach by selectively targeting the most toxic and destructive form of amyloid-beta, the oligomers. Despite claims of precision targeting, other antibodies have consistently shown binding to multiple forms of amyloid-beta, including plaque, resulting in a significant incidence of ARIA. If PMN310 is able to shift the benefit-risk profile as compared to the existing standard of care, with ARIA rates similar to placebo and, at a minimum, similar efficacy, we believe PMN310 could be positioned to take a leadership position in the treatment not only of early AD patients, but potentially of asymptomatic (preclinical) AD patients.”</p>     <p align="left" style="text-align:left;">“With PRECISE-AD closing out its final stage of patient visits, we look forward to reporting topline data in the first quarter of 2027, which will include safety, biomarker and clinical efficacy measures. PMN310’s Fast Track Designation allows for more frequent engagement with the United States Food and Drug Administration (FDA), and we plan to request a meeting with the agency next year, after the full data set has been analyzed. In parallel, we are advancing development of a subcutaneous formulation of PMN310 and preparing for a registrational study that, subject to FDA feedback, we anticipate initiating toward the end of 2027.”</p>     <p align="left" style="text-align:left;"><strong>Corporate Highlights</strong></p>     <p align="left" style="text-align:left;"><strong><em>Alzheimer’s Disease (AD) Program (PMN310) — PRECISE-AD Interim Data and Development Update</em></strong></p>     <ul type="disc"><li>The Company believes that PMN310 has a differentiated design based on (1) selectivity: in preclinical studies, PMN310 bound toxic amyloid-beta oligomers while avoiding monomers, fibrils and plaque; and (2) antibody structure: an IgG1 backbone, as used by lecanemab and donanemab, intended to support Fc receptor–mediated microglial effector function. Together with the encouraging blinded interim safety observations described below, these features support a distinct clinical hypothesis.</li></ul>     <ul type="disc"><li>At AAIC 2026, ProMIS presented the first human evidence of amyloid-beta oligomer target engagement by PMN310 from its Phase 1a study in healthy volunteers, showing a dose-dependent reduction in detectable amyloid-beta oligomers in cerebrospinal fluid after PMN310 administration.</li></ul>     <ul type="disc"><li>On July 28, 2026, ProMIS reported encouraging blinded six-month interim safety and biomarker results from PRECISE-AD in 136 patients: no ARIA-E as of the data cutoff in any APOE genotype (including 11% APOE4 homozygotes), ARIA-H of 4.4% (all mild and asymptomatic), no drug-related discontinuations or treatment-related serious adverse events, and a decrease from baseline of approximately 15% in plasma pTau217 and 13.3% in CSF MTBR-tau243 in the pooled, blinded population.</li></ul>     <ul type="disc"><li>At topline data, the Company will evaluate the totality of the data for evidence of an improved benefit-risk profile. Encouraging signals would include (1) safety, with ARIA and drug-related adverse event rates comparable to background or placebo; (2) clinical efficacy, with a directional slowing of disease progression versus placebo on iADRS or CDR-SB that is similar to existing therapies at 12 months; and (3) biomarker changes that directionally align with PMN310’s oligomer-targeted mechanism.</li></ul>     <ul type="disc"><li>Development of a subcutaneous formulation is underway to support patient convenience and access, with the intent to incorporate it into the next phase of PMN310 clinical development.</li></ul>     <p align="left" style="text-align:left;"><strong><em>Pipeline Progress and Scientific Presentations</em></strong></p>     <ul type="disc"><li>PMN267 (ALS): The program targeting misfolded TDP-43 continues to advance the lead humanized monoclonal antibody PMN267 for extracellular administration and an intrabody format for intracellular delivery.</li></ul>     <ul type="disc"><li>PMN442 (Dementia with Lewy Bodies, Parkinson’s Disease, Multiple System Atrophy): PMN442, the Company’s lead candidate for synucleinopathies, was selected based on its selective binding and protective activity against pathogenic forms of alpha-synuclein and has been humanized in a human IgG1 framework for advancement to IND-enabling studies.</li></ul>     <ul type="disc"><li>Vaccine programs: ProMIS has selected several lead vaccine candidates, PMN311, targeting toxic amyloid-beta oligomers in AD; PMN440, targeting pathogenic alpha-synuclein across multiple synucleinopathies; and PMN260, targeting misfolded TDP-43. All vaccines have shown robust immunogenicity in mouse vaccination studies. Recently completed studies in mouse models of synucleinopathy have demonstrated protective activity by PMN440.</li></ul>     <p align="left" style="text-align:left;"><strong><em>Corporate and Investor Activities</em></strong></p>     <ul type="disc"><li>Appointed Ivana Rubino, Ph.D., a former senior Biogen and Roche executive with more than 15 years of global neuroscience and Alzheimer’s disease leadership experience, as Chief Commercial Officer, effective October 5, 2026. Dr. Rubino will help guide the Company’s regulatory, late-stage development and commercial strategy as it continues to advance PMN310.</li></ul>     <ul type="disc"><li>Management participated in six healthcare investor conferences, including Cantor and H.C. Wainwright. Mr. Warma also participated in the Lausanne XIII Workshop in Lausanne, Switzerland, and marked World Alzheimer’s Day on September 21, 2026, with a Nasdaq interview in New York.</li></ul>     <p align="left" style="text-align:left;"><strong><em>Future Activities and Upcoming Milestones</em></strong></p>     <ul type="disc"><li>The PRECISE-AD six-month interim data were selected for poster presentation at the 2026 Clinical Trials in Alzheimer’s Disease (CTAD) conference, taking place November 16–19, 2026, in Boston.</li></ul>     <ul type="disc"><li>Abstracts on the PRECISE-AD trial and on the activity of the PMN440 alpha-synuclein vaccine have been selected for platform presentations at the 2027 AD/PD conference.</li></ul>     <ul type="disc"><li>Completion of all PRECISE-AD patient visits, expected in the fourth quarter of 2026.</li></ul>     <ul type="disc"><li>Presentation of unblinded 12-month topline data from PRECISE-AD, anticipated in the first quarter of 2027.</li></ul>     <p align="left" style="text-align:left;"><strong><em>Third Quarter 2026 Financial Highlights</em></strong></p>     <ul type="disc"><li>Cash Position: Cash was $44.1 million as of September 30, 2026, compared to $6.1 million as of December 31, 2025, reflecting net proceeds of $70.1 million from the Company’s January 2026 private placement.</li></ul>     <ul type="disc"><li>Cash Runway: Based on its current operating plan, the Company expects that its existing cash will be sufficient to fund operating expenses and capital expenditure requirements through 2027, well beyond the anticipated first quarter 2027 PRECISE-AD topline data readout.</li></ul>     <ul type="disc"><li>Research and Development (R&amp;D) Expenses: R&amp;D expenses were $6.7 million for the three months ended September 30, 2026, compared to $9.8 million for the same period in 2025. The 32% decrease was primarily attributable to a $3.6 million decrease in direct PMN310 expenses as PRECISE-AD progressed toward completion of patient visits during 2026, partially offset by increased activity in the ALS and platform programs.</li></ul>     <ul type="disc"><li>General and Administrative (G&amp;A) Expenses: G&amp;A expenses were $1.9 million for the three months ended September 30, 2026, compared to $2.0 million for the same period in 2025. Lower professional and consulting fees were largely offset by higher employee salaries and benefits from additional headcount.</li></ul>     <ul type="disc"><li>Other Income: Other income was $0.5 million for the three months ended September 30, 2026, compared to $0.2 million for the same period in 2025, due to higher interest income on higher cash balances.</li></ul>     <ul type="disc"><li>Net Loss: Net loss was $8.2 million, or $(0.89) per basic and diluted share, for the three months ended September 30, 2026, compared to $11.6 million, or $(5.93) per basic and diluted share, for the same period in 2025. For the nine months ended September 30, 2026, net loss was $28.1 million, or $(3.39) per basic and diluted share, compared to $29.0 million, or $(19.58) per basic and diluted share, for the same period in 2025.</li></ul>     <p align="left" style="text-align:left;">Additional information is available in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the U.S.<br>Securities and Exchange Commission (SEC) and available at www.sec.gov and on SEDAR+ at www.sedarplus.ca.</p>       <p align="left" style="text-align:left;"><strong>About ProMIS Neurosciences Inc.</strong><br><br>ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).<br><br><strong>About PMN310 and the PRECISE-AD Trial for Alzheimer’s Disease (AD)</strong><br><br>PMN310, the Company’s lead product candidate for the treatment of AD, is a humanized IgG1 monoclonal antibody designed to selectively target toxic misfolded oligomers while avoiding monomers, fibrils and plaque, potentially reducing or eliminating amyloid-related imaging abnormalities (ARIA) liability associated with plaque binding. Its differentiated target selectivity and IgG1 backbone may offer an optimized benefit-risk profile over other amyloid-directed antibody therapeutics. PMN310 was granted Fast Track designation by the U.S. Food and Drug Administration in July 2025.<br><br>PRECISE-AD (NCT06750432) is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety, tolerability, and pharmacokinetics of multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310 in patients with mild cognitive impairment due to AD or mild AD (Stage 3 and Stage 4 AD). PRECISE-AD is the first study to examine the effects of a monoclonal antibody directed solely against Aβ oligomers on biomarkers associated with AD pathology and clinical outcomes. Safety is a primary outcome with particular emphasis on characterizing the incidence of ARIA in patients receiving a non-plaque-binding antibody. The study is powered to provide 95% confidence for detection of ARIA and is designed to provide meaningful insight into the effects of PMN310 on biomarkers and clinical outcomes.<br><br><strong>EpiSelect™ Drug Discovery Engine</strong><br><br>Toxic misfolded proteins underlie the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). Generation of therapeutic antibodies selectively targeting only disease-misfolded protein isoforms, while sparing normal or irrelevant isoforms of the same protein, has not yet been successfully achieved by conventional immunization strategies. ProMIS Neurosciences has developed a computational platform (EpiSelect™) to identify conformational epitopes that are uniquely exposed on toxic misfolded proteins, which can then be used to generate misfolding-specific antibodies or vaccine formulations.<br><br><strong>Forward-Looking Statements</strong><br><br>This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, “forward-looking information”) within the meaning of applicable securities laws. Statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Company’s PRECISE-AD Phase 1b clinical trial; the interpretation and clinical significance of the blinded six-month interim safety and biomarker data (including ARIA, pTau217, and MTBR-tau243 findings) described in this release; the expected timing and nature of topline clinical data of PMN310 and the criteria by which the Company will evaluate those results; the anticipated timing and potential outcomes of interactions with the FDA, including a planned meeting in 2027, and the potential benefits of Fast Track Designation; the development of a subcutaneous formulation, its potential benefits, and the Company’s plans to incorporate it into future clinical development; PMN310’s mechanism of action and potential benefits; the potential for PMN310 to offer a differentiated efficacy and safety profile relative to plaque-directed antibodies and other oligomer-directed antibodies; the potential clinical utility and competitive positioning of PMN310, including its potential to achieve a leadership position in the treatment of early AD and its potential use in asymptomatic or preclinical AD, including with respect to comparisons made to existing approved treatments or candidates in development; the Company’s belief that toxic soluble amyloid-beta oligomers are a primary driver of cognitive decline in AD; the advancement, development plans and potential therapeutic benefits of the Company’s preclinical antibody, intrabody and vaccine programs, including PMN267, PMN442, PMN311, PMN440 and PMN260; and the Company’s expectation that existing cash resources will fund planned operations through 2027. Statements containing forward-looking information are not historical facts but instead represent management’s current expectations, estimates, and projections regarding the future of the business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions, and other factors that may cause actual results, level of activity, performance or achievement to differ materially from those expressed or implied, including, but not limited to, the risk that early or interim results may not be indicative of final or topline results, the Company’s accumulated deficit, and the expectation for continued losses. Important factors that could cause actual results to differ materially are discussed in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K and in its subsequent filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p>          <p>&nbsp;</p>     <p align="justify" style="text-align:justify;"><strong>Condensed Consolidated Balance Sheets (Unaudited)</strong></p>   <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;">
<tbody><tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>&nbsp;</strong></td>
<td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>September 30, 2026</strong></td>
<td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>December 31, 2025</strong></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "><strong>Assets</strong></td>
<td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>&nbsp;</strong></td>
<td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>&nbsp;</strong></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Cash</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">$44,073,222</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">$6,116,556</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Short-term investments</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">33,753</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">33,753</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Prepaid expenses and other current assets</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">3,053,943</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">3,032,112</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "><strong>Total current assets</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$47,160,918</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$9,182,421</strong></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "><strong>Total assets</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$47,160,918</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$9,182,421</strong></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "><strong>Liabilities and Shareholders’ Equity</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>&nbsp;</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>&nbsp;</strong></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Accounts payable</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">$485,127</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">$2,543,415</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Accrued liabilities</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">4,857,759</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">7,868,416</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "><strong>Total current liabilities</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$5,342,886</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$10,411,831</strong></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Share-based compensation liability</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">56,368</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">29,182</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "><strong>Total liabilities</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$5,399,254</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$10,441,013</strong></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Additional paid-in capital</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">200,674,965</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">129,518,812</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Accumulated other comprehensive loss</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">(371,184)</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">(371,184)</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Accumulated deficit</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">(158,542,117)</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">(130,406,220)</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "><strong>Total shareholders’ equity (deficit)</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$41,761,664</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$(1,258,592)</strong></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "><strong>Total liabilities and shareholders’ equity (deficit)</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$47,160,918</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$9,182,421</strong></td>
</tr>
</tbody></table>   <p align="justify" style="text-align: justify;">&nbsp;</p>     <p align="justify" style="text-align:justify;"><strong>Condensed Consolidated Statements of Operations (Unaudited)</strong></p>   <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;">
<tbody><tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: bottom ; "><strong>&nbsp;</strong></td>
<td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three Months Ended September 30, 2026</strong></td>
<td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>Three Months Ended September 30, 2025</strong></td>
<td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>Nine Months Ended September 30, 2026</strong></td>
<td style="border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: bottom ; "><strong>Nine Months Ended September 30, 2025</strong></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Research and development</td>
<td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: middle ; ">$6,710,035</td>
<td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: middle ; ">$9,797,418</td>
<td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: middle ; ">$23,202,834</td>
<td style="border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; vertical-align: middle ; ">$24,011,452</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">General and administrative</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">1,905,389</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">1,953,014</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">6,323,886</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">5,383,737</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "><strong>Total operating expenses</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$8,615,424</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$11,750,432</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$29,526,720</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$29,395,189</strong></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "><strong>Loss from operations</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>(8,615,424)</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>(11,750,432)</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>(29,526,720)</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>(29,395,189)</strong></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Other income</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">453,556</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">170,306</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">1,390,823</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">350,130</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "><strong>Net loss</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$(8,161,868)</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$(11,580,126)</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$(28,135,897)</strong></td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "><strong>$(29,045,059)</strong></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Net loss per share, basic and diluted</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">$(0.89)</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">$(5.93)</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">$(3.39)</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">$(19.58)</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; ">Weighted-average outstanding Common Shares, basic and diluted</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">9,143,340</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">1,953,352</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">8,303,704</td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; ">1,483,150</td>
</tr>
</tbody></table>   <p><strong><br>For Investor Relations, please contact:</strong></p>     <p align="justify" style="text-align:justify;">Carie Pierce<br>VP, Investor Relations &amp; External Affairs<br>IR@promisneurosciences.com</p>   <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/26bec3c9-ac4b-487b-ab90-3b62be29497d"><img src="https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg" border="0" width="150" height="63" alt="Primary Logo"></a></p>
Source: ProMIS Neurosciences Inc.

]]></content:encoded>
                            </item>
                    <item>
                <title><![CDATA[ProMIS Neurosciences to Participate in Upcoming Conferences in November]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.promisneurosciences.com/news-media/press-releases/detail/278/promis-neurosciences-to-participate-in-upcoming-conferences</link>
                <pubDate>Thu, 05 Nov 26 07:00:00 -0500</pubDate>
                <guid>https://www.promisneurosciences.com/news-media/press-releases/detail/278/promis-neurosciences-to-participate-in-upcoming-conferences</guid>
                                                                                    <content:encoded><![CDATA[

<p align="left" style="text-align:left;">CAMBRIDGE, Mass., Nov.  05, 2026  (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming November 2026 conferences. Presentations and fireside chats will be delivered by Neil Warma, President and Chief Executive Officer. Members of the Company’s leadership team will be available for one-on-one meetings at the conferences.</p>     <p align="left" style="text-align:left;"><strong>Conference details below:&nbsp;</strong></p>     <p align="left" style="text-align:left;"><strong>November 9-11: Guggenheim 3</strong><sup><strong>rd</strong></sup><strong> Annual Healthcare Innovation Conference </strong><br>Location: Boston, MA<br>Fireside chat: Tuesday, November 10, 2:30 p.m. ET, Wheeler Room<br>Webcast link: <a href="https://www.globenewswire.com/Tracker?data=PuBt1n2R-2v2uyf84LXhFAJQkUD1xt2qtc0DKIotvTnXIYhz4C0weFgj5wmjhqpDu-ZrvJvn1A9oxLWCHFwvtLBKHaUg84gYfYzebbneS1xhXI9R67IR1-Thi9OhzdMwpLtu8YBVcQeazbxspZfVdFxiM705EF77dAYEWvV4UaxyQfh0H798_USoKu1PdWWN" rel="nofollow" target="_blank"><strong><u>Click Here</u></strong></a></p>     <p align="left" style="text-align:left;"><strong>November 10-12: Stifel 2026 Healthcare Conference</strong><br>Location: New York, NY<br>Presentation: Wednesday, November 11, 2:40 p.m. ET, Spellman Room<br>Webcast link: <a href="https://www.globenewswire.com/Tracker?data=PuBt1n2R-2v2uyf84LXhFDMOh-rK6PO6R38UrR4wYCg9Bpmu9xzvXU66rIhi5uvTCjRMlZJeTNkuR0D-t6Yps7xZOfCHIQFlBsMRG8Z9zfh0Yly00OvLky9bO_B7IK90IMqPPEPJ3f6uLz8ThMvzgdOPnAZaLFkKOkc645kQdTIhqEVV2uB1VNRwEEzvXqWb" rel="nofollow" target="_blank"><strong><u>Click Here</u></strong></a></p>     <p align="left" style="text-align:left;"><strong>November 16-17: UBS Global Biopharma Conference</strong><br>Location: London, UK<br>Presentation: Monday, November 16, 10 a.m. GMT <br>Webcast link: <a href="https://www.globenewswire.com/Tracker?data=PuBt1n2R-2v2uyf84LXhFJoHCutwEo5zAUGc92226MHqUdc17-T4gOCdiHOzi9FU3Ky6DYgregIdmOhRSPDnouy_0ttXdqJUUD7pKBYNq7J7AJepgMG4PJmyxW3E8C4R2j3dO9InMoFF-KoTDiGS0A==" rel="nofollow" target="_blank"><strong><u>Click Here</u></strong></a></p>     <p align="left" style="text-align:left;"><strong>November 16-19: Jefferies Global Healthcare Conference</strong><br>Location: London, UK</p>     <p align="left" style="text-align:left;"><strong>November 16-19: Clinical Trials on Alzheimer’s Disease (CTAD) Conference</strong><br>Location: Boston, MA<br>Poster presentation: Monday, Nov 16-Tues Nov 17th<br>Poster title: Poster # P047, Interim Safety and Biomarker Analysis of PRECISE-AD* <br>(*data previously presented on July 28, 2026)</p>     <p align="left" style="text-align:left;"><strong>November 30-December 2: 9th Annual Evercore Healthcare Conference</strong><br>Location: Miami, FL<br>Fireside chat: Wednesday, December 2, 9:10 a.m. ET, Sevilla A<br>Webcast link: <a href="https://www.globenewswire.com/Tracker?data=PuBt1n2R-2v2uyf84LXhFHeu6WV8eTQsv2XhNQSxD46VXKLxRwZYOd6tpk-S0M4ZfmvYnSAFqUifxYdB21LKSQ0NPDgMsfCFqnownD3ssMj5AbWAC5yUrR0k6NC8SS-NqDNV7ytaj5pdRMGYNAAAdg3Ep6dGfHUOVAGSopNrODL3QMXK0HYy9u_eyQ13MZxL" rel="nofollow" target="_blank"><strong><u>Click Here</u></strong></a></p>     <p align="left" style="text-align:left;"><strong>About ProMIS Neurosciences Inc.</strong></p>     <p align="left" style="text-align:left;">ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS’ lead asset in Phase 1b development, PMN310, is a humanized IgG1 monoclonal antibody designed to selectively target only the toxic oligomers of amyloid-beta (AβOs), believed to be among the earliest and most damaging drivers of Alzheimer’s disease, while avoiding binding to amyloid plaques and vascular deposits. ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).</p>     <p align="left" style="text-align:left;"><strong>Investor Relations Contact:</strong></p>     <p align="left" style="text-align:left;">Carie Pierce, VP, Investor Relations &amp; External Affairs</p>     <p align="left" style="text-align:left;">IR@promisneurosciences.com</p>   <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/26bec3c9-ac4b-487b-ab90-3b62be29497d"><img src="https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg" border="0" width="150" height="63" alt="Primary Logo"></a></p>
Source: ProMIS Neurosciences Inc.

]]></content:encoded>
                            </item>
                    <item>
                <title><![CDATA[ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.promisneurosciences.com/news-media/press-releases/detail/277/promis-neurosciences-to-report-third-quarter-2026-financial</link>
                <pubDate>Tue, 03 Nov 26 07:00:00 -0500</pubDate>
                <guid>https://www.promisneurosciences.com/news-media/press-releases/detail/277/promis-neurosciences-to-report-third-quarter-2026-financial</guid>
                                                                                    <content:encoded><![CDATA[

<h3 class="spr-ir-news-article-title">Company to host investor conference call and webcast at 4:30 p.m. ET.</h3>

<p align="left" style="text-align:left;">Cambridge, Massachusetts, Nov.  03, 2026  (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the third quarter ended September 30, 2026, and provide corporate updates on November 12, 2026.&nbsp; The company will host a conference call and webcast on the same day at 4:30 p.m. ET.</p>      <p align="left" style="text-align:left;"><b><u>Conference Call and Webcast Information: </u></b></p>    <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;">
<tbody><tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "> <b>Date:</b> </td>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "> November 12, 2026 </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "> <b>Time:</b> </td>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "> 4:30 p.m. Eastern Time </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "> <b>Dial-in:</b> </td>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "> 1-877-407-9208 (U.S. Investors)<br>1-201-493-6784 (International)  </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "> <b>Conference I.D.:</b> </td>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "> 13762779 </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "> <b>CallMe</b><sup><b>TM</b></sup><b>:</b> </td>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "> <a href="https://callme.viavid.com/viavid/?%24Y2FsbG1lPXRydWUmcGFzc2NvZGU9MTM3NjE4MTImaD10cnVlJmluZm89Y29tcGFueS1lbWFpbCZyPXRydWUmQj02" rel="nofollow" target="_blank"><u>Click Here</u></a> </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "> <b>Webcast:</b> </td>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "> <a href="https://viavid.webcasts.com/starthere.jsp?ei=1776913&amp;tp_key=4469e0ed52" rel="nofollow" target="_blank"><u>Click Here</u></a> </td>
</tr>
</tbody></table>     <p align="left" style="text-align:left;"><br>A replay of the webcast will be available in the Investors section of the ProMIS website following the completion of the call. </p>      <p align="left" style="text-align:left;">ProMIS has also published an investor Q&amp;A outlining the scientific rationale that differentiates PMN310 from other amyloid-targeting approaches, available in the Investors section of the ProMIS website: <a href="https://www.globenewswire.com/Tracker?data=OmG56UR0Epz7hPT_Dqf_uRISBB4C89R73ikQrmjKuji3kkZ72QD7ZobXsd3BpYvYlSayiXk0ws3f6bIu03CThWKVJxEiOQSdWQDwwheU91TO8f0184w1Vbw42eA4SW912nzcf6VibMK1ujOLAvQfGYdTpIZCWd2JkkB2a6BPjIdKjdBsZvjNPIPgyy2zNSxcvXC73YsP-KU4Sq5iTuzh9AA0EV0IolcYkcFBnjtZCNAKuwqaszl2NQzh_0GZHQsJvN7VhO8r1BD0bV1M9E1Ai_ED7X6lxhM5eQQNr1gKW59xmwPg0Eqnvh8IL-eGO6C1A0Mv0fz1c18TRinVjzfForCndvCJZjjTUGiQGfbF8-7P3-rglpGZOnyAiEgmC-81YDe2_pwwSysTaJNIe35a5nEpP_sRMmL7hQqAINZzRqWLdi3FD2XVIOTLKscKWxWu" rel="nofollow" target="_blank"><u>PMN310 Scientific and Clinical Update (November 2026)</u></a>.</p>      <p align="left" style="text-align:left;"><b>About ProMIS Neurosciences Inc.</b></p>     <p align="left" style="text-align:left;">ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS’ lead asset in Phase 1b development, PMN310, is a humanized IgG1 monoclonal antibody designed to selectively target only the toxic oligomers of amyloid-beta (AβOs), believed to be among the earliest and most damaging drivers of Alzheimer’s disease, while avoiding binding to amyloid plaques and vascular deposits. ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).</p>      <p align="left" style="text-align:left;"><b>Investor Relations Contact</b><br>Carie Pierce<br>VP Investor Relations &amp; External Affairs<br><a href="https://www.globenewswire.com/Tracker?data=3eXuBdxCbaG5kpCvyE9P0N7AOjShoMgXIj3D8N3Rn31z_HENn0L2FZp65joqHBK7ewruCiHJuWmMIppm8jKlQKN5RbUd9yAPj2Ec62jjTJsICafPV1i_raBCnugny6FO" rel="nofollow" target="_blank">IR@ProMISNeurosciences.com</a></p>      <p align="left" style="text-align:left;"><b>Media Contact</b><br>Maggie Whitney<br>LifeSci Communications<br><a href="https://www.globenewswire.com/Tracker?data=mVxG6TgGB3TuDHMv-Rzsnx5HVLsD0XoKDxHVHo5C0h6ZNnjsw2iaAK2yXVAsf50dYvBQgX3dZwOvF1Fc8QUKlOF4wss90_QJJoSG0XO5COKZywWIHOcf9vEzifErMFWx" rel="nofollow" target="_blank"><u>mwhitney@lifescicomms.com</u></a></p>      <p align="left" style="text-align:left;"><b>For further information:</b><br>Visit us at <a href="https://www.globenewswire.com/Tracker?data=np9O3qB-HlpGoi4hHvEtRWJ-YL9N8pM43LA_r3mm8k4yMPK_XRWcTIxeeY_VO5KD1gFrzhZd8jXHbFPMytKC22BrPfRSC7-ySx2maWKUJQvS4JBo8FZU9Ndi6HCbTzsv" rel="nofollow" target="_blank"><u>www.promisneurosciences.com</u></a></p>    <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/26bec3c9-ac4b-487b-ab90-3b62be29497d"><img src="https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg" border="0" width="150" height="63" alt="Primary Logo"></a></p>
Source: ProMIS Neurosciences Inc.

]]></content:encoded>
                            </item>
                    <item>
                <title><![CDATA[ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.promisneurosciences.com/news-media/press-releases/detail/276/promis-neurosciences-appoints-seasoned-alzheimers-and</link>
                <pubDate>Tue, 06 Oct 26 07:05:00 -0400</pubDate>
                <guid>https://www.promisneurosciences.com/news-media/press-releases/detail/276/promis-neurosciences-appoints-seasoned-alzheimers-and</guid>
                                                                                    <content:encoded><![CDATA[

<p align="center"><em>Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy</em></p>     <p align="center"><em>Appointment strengthens commercial and development leadership as PMN310 advances toward 12-month topline data expected in Q1 2027</em></p>     <p align="justify">CAMBRIDGE, Mass.,, Oct.  06, 2026  (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company developing therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, including Alzheimer’s disease, today announced the appointment of Ivana Rubino, Ph.D., as Chief Commercial Officer, effective October 5, 2026.<br><br>Dr. Rubino brings more than 15 years of global biopharmaceutical leadership experience, with deep expertise in neuroscience and particularly in Alzheimer’s disease, spanning clinical development strategy, medical affairs, launch readiness, market development and commercialization. During her time at Biogen and F. Hoffmann-La Roche, Dr. Rubino led and helped shape Alzheimer’s disease programs across late-stage development, scientific and medical strategy, market preparation and commercialization planning. Her experience includes global leadership supporting the LEQEMBI® franchise, preparation for next-generation Alzheimer’s therapies, and the build-out of large global medical organizations across the United States, Europe and other major markets. She also held senior global leadership roles across multiple sclerosis, spinal muscular atrophy and neuropsychiatry.<br><br>“Ivana joins ProMIS at an important point in the evolution of PMN310 and our Alzheimer’s program,” said Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences. “She brings a rare combination of scientific depth and experience advancing major Alzheimer’s programs through launch readiness and commercialization at Biogen and Roche. Ivana’s broad neuroscience and strategic experience will help us build the capabilities needed for ProMIS’ next stage of growth, and her extensive background in Alzheimer’s disease will be particularly valuable as we move toward our 12-month PRECISE-AD topline readout of PMN310 in the first quarter of 2027.”<br><br>As Chief Commercial Officer, Dr. Rubino will lead ProMIS’ commercial and market preparation strategy for PMN310, including market access and payer planning, patient and physician pathway development, key opinion leader and advocacy engagement, launch readiness and lifecycle strategy. She will also work closely with the Chief Medical Officer on pivotal development strategy and evidence generation, and will contribute to regulatory strategy, business development and the positioning of ProMIS’ broader neuroscience pipeline.<br><br>“Neuroscience has been at the center of my career, and I have had the privilege of working across several areas in which major scientific advances have transformed what is possible for patients,” said Dr. Rubino. “Alzheimer’s disease is perhaps one of the clearest examples: although we have made significant progress, meaningful scientific, clinical and access challenges remain. What attracted me to ProMIS was both the differentiated science behind PMN310 and the broader potential of the company’s approach to targeting toxic misfolded proteins. If the clinical data in the ongoing Alzheimer’s trial continue to be supportive, PMN310 could represent an important next step in Alzheimer’s treatment. I am excited to help translate the science into development and commercial strategies that can ultimately create meaningful value for patients, families and the neuroscience community.”<br><br>Dr. Rubino joins ProMIS from Biogen, where she most recently served as Vice President and Global Head, Alzheimer’s Disease &amp; Multiple Sclerosis Medical, leading global medical strategy, launch readiness and lifecycle optimization, serving as alliance medical strategy leader with Eisai, and supporting the global development and expansion of LEQEMBI, including 52 market approvals.<br><br>Previously at Biogen, Dr. Rubino held senior global leadership roles across Alzheimer’s disease, neuropsychiatry and neuromuscular disease. She built and scaled a global Alzheimer’s disease medical organization of more than 100 professionals, and served as Executive Director, Global Head of Medical – Alzheimer’s Disease &amp; Neuromuscular Disease.<br><br>Prior to Biogen, Dr. Rubino held a series of increasingly senior medical affairs, commercial and regulatory roles at F. Hoffmann-La Roche AG in Basel, Switzerland, across Alzheimer’s disease, spinal muscular atrophy, multiple sclerosis and neuropsychiatry.<br><br>Dr. Rubino holds a Ph.D. in Immunology and Molecular Biology from the University of Lausanne, an M.Sc. in Cellular and Molecular Biology from the University of Milan, and an M.Sc. in Genetics from the University of Paris VII.<br><br><strong>Inducement Grant</strong><br><br>In connection with Dr. Rubino’s appointment, effective October 5, 2026, ProMIS granted Dr. Rubino an inducement award of a non-qualified stock option to purchase 80,000 of the Company’s common shares in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement award has an exercise price of $9.37 per share, which is equal to the closing price of the Company’s common shares as reported by Nasdaq on October 5, 2026. The option has a 10-year term; 25% of the underlying shares vested on Dr. Rubino’s hire date and the remainder vest in equal monthly installments over the subsequent 36 months, subject to continued service. The option is subject to the terms of the Company’s 2026 Inducement Plan and the applicable stock option agreement.<br><br><strong>About PMN310</strong><br>PMN310 is ProMIS’ lead investigational antibody for Alzheimer’s disease. It is a humanized monoclonal antibody designed to selectively recognize toxic amyloid-beta oligomers while avoiding monomers and amyloid plaque. ProMIS is evaluating PMN310 in the PRECISE-AD Phase 1b clinical study in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease, with unblinded 12-month topline results expected in the first quarter of 2027. The Company is also advancing development of a subcutaneous formulation intended to support greater convenience and flexibility in future treatment.<br><br><strong>About ProMIS Neurosciences Inc.</strong><br>ProMIS Neurosciences Inc. is a clinical-stage biotechnology company developing therapeutic antibodies and vaccines targeting toxic misfolded proteins implicated in neurodegenerative diseases. Its proprietary discovery platform is designed to identify disease-specific epitopes on misfolded proteins and has generated programs in Alzheimer’s disease and other neurodegenerative disorders.<br><br><strong>Forward-Looking Statements</strong><br>This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the timing and results of clinical trials; the potential therapeutic, safety, access and commercial profile of PMN310; the expected timing and nature of topline clinical data of PMN310; development of a subcutaneous formulation; future clinical, regulatory and commercialization plans; and the expected contributions of Dr. Rubino. These statements reflect current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including risks described in ProMIS’ filings with the U.S. Securities and Exchange Commission. ProMIS undertakes no obligation to update forward-looking statements except as required by law.<br><br><strong>Contacts</strong><br><strong>Investor Relations</strong><br>ProMIS Neurosciences Inc.<br>IR@promisneurosciences.com</p>            <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/26bec3c9-ac4b-487b-ab90-3b62be29497d"><img src="https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg" border="0" width="150" height="63" alt="Primary Logo"></a></p>
Source: ProMIS Neurosciences Inc.

]]></content:encoded>
                            </item>
                    <item>
                <title><![CDATA[Upcoming Conferences and Events in October]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.promisneurosciences.com/news-media/press-releases/detail/275/upcoming-conferences-and-events-in-october</link>
                <pubDate>Wed, 30 Sep 26 08:00:00 -0400</pubDate>
                <guid>https://www.promisneurosciences.com/news-media/press-releases/detail/275/upcoming-conferences-and-events-in-october</guid>
                                                                                    <content:encoded><![CDATA[<p><b>CAMBRIDGE</b>, <b>Mass., September 30, 2026</b> – ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming October 2026 conferences and events, and will be available for one-on-one meetings.</p>
<p><b>Details are as follows: </b></p>
<p><b>H.C. Wainwright Biotech On Tap 2026&nbsp;<br></b><b>Date: </b>September 30-October 2<br><b></b><b>Location</b>: Munich, Germany<br><b>Participant</b>: Neil Warma, Chief Executive Officer, ProMIS Neurosciences<b></b></p>
<p><b>Lausanne XIII 13<sup>th</sup> Annual Workshop<br></b><b>Date: </b>October 6-8, 2026<br><b></b><b>Location</b>: Lausanne, Switzerland<br><b>Participant:</b> Neil Warma, Chief Executive Officer, ProMIS Neurosciences</p>
<p>The Lausanne Workshop is an annual global convening dedicated to stopping Alzheimer's disease. Since 2014, it has united leaders from industry, government, academia, and civil society to drive candid, solutions-focused dialogue.<b></b></p>
<p><b>Chardan’s 10<sup>th</sup> Annual Healthcare Conference<br></b><b>Date:</b> Tuesday, October 20, 2 pm. ET<br><b>Location</b>: New York, NY<br><b>Panel</b> <b>title</b>: Targeting Neurodegenerative &amp; Neuromuscular Disease: ALS, DMD, Alzheimer's &amp; Parkinson's<br><b>Participants</b>: Larry Altstiel, Chief Medical Officer, ProMIS Neurosciences; Moderated by Keay Nakae, Director of Research and a Senior Research Analyst at <a href="https://www.prnewswire.com/news-releases/chardan-capital-markets-expands-research-division-with-appointment-of-keay-nakae-senior-research-analyst--healthcare-300023556.html" target="_blank" rel="noopener">Chardan Capital Markets</a><b></b></p>
<p><b>Greater Boston Walk to End Alzheimer’s<br></b>Date: Sunday, October 25<br>Location: Cambridge, MA</p>
<p><b>About ProMIS Neurosciences Inc.</b></p>
<p>ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS’ lead asset in Phase 1b development, PMN310, is a humanized IgG1 monoclonal antibody designed to selectively target only the toxic oligomers of amyloid-beta (AβOs), believed to be among the earliest and most damaging drivers of Alzheimer’s disease, while avoiding binding to amyloid plaques and vascular deposits. ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).</p>
<p><b>Investor Relations Contact:</b></p>
<p>Carie Pierce, VP, Investor Relations &amp; External Affairs<br>IR@promisneurosciences.com</p>]]></content:encoded>
                            </item>
                    <item>
                <title><![CDATA[ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.promisneurosciences.com/news-media/press-releases/detail/274/promis-neurosciences-to-participate-in-upcoming-conferences</link>
                <pubDate>Tue, 01 Sep 26 08:00:00 -0400</pubDate>
                <guid>https://www.promisneurosciences.com/news-media/press-releases/detail/274/promis-neurosciences-to-participate-in-upcoming-conferences</guid>
                                                                                    <content:encoded><![CDATA[

<p align="left">CAMBRIDGE, Mass, Sept.  01, 2026  (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings.</p>      <p align="left"><strong>Conference details below: </strong></p>      <p align="left"><strong>September 9-11: Cantor Global Healthcare Conference</strong><br>Location: New York, NY<br>Fireside Chat: Wednesday, September 9, 9:10-9:40 a.m. ET<br>Participants: Pete Stavropoulos, Cantor analyst, and Neil Warma, ProMIS President &amp; Chief Executive Officer<br>Webcast link: <a href="https://www.globenewswire.com/Tracker?data=8g0TB6Gjb7IPuhBxTwLy4Mxm_JCeRHAp8XmSLb7CNIsL3fKfdqzI4-5kW3zZJ_ORtVCfdDnTa00vfxpODnk9JQcKGlwS6VEBoythQe0SY8o0pKgNkA2YwLf3btkbPrA6ma0PAbltUowTkxHeGBfQyjp9LNeXFQsorl0HBGFSsvvtxc1XkOOL8KkA26Uqvez2EMeQrNskYSxt-9LVm3OmtBBl0AOXKXXE07I4MyckNDhqMsB2Ou-S6qffYoY3yRSx" rel="nofollow" target="_blank"><strong><u>Click Here</u></strong></a><br><br><strong>September 9-10: Moody Capital Disruptive Growth &amp; Life Sciences Conference</strong><br>Location: New York, NY<br>Presentation: Thursday, September 10, 1:45-2:05 p.m. ET, Room 1<br>Webcast link: <a href="https://www.globenewswire.com/Tracker?data=8g0TB6Gjb7IPuhBxTwLy4IKMIvE6X8YWoEXKlYKaOJt9U8yPTPCchkHih5eziW17c1RLg5mXuBHsh_T3ye-e4spV-Fdx6x2zLVBVAxjZNKil3NS7C3fizviQLd-1W69oW0zxuTdf60_O7M8Z7zUFNFBTYrpCUJkXM1ZQ47gYdKUj6MaWImnkrmA4RFs3_Gn0" rel="nofollow" target="_blank"><strong><u>Click Here</u></strong></a><br><br><strong>September 14-16: H.C. Wainwright 28</strong><sup><strong>th</strong></sup><strong> Annual Global Investment Conference</strong><br>Location: New York, NY<br>Presentation: Tuesday, September 15, 10:30-11:00 a.m. ET, Louis Room (4<sup>th</sup> floor)<br>Webcast link: <a href="https://www.globenewswire.com/Tracker?data=8g0TB6Gjb7IPuhBxTwLy4N3Gt6XmOkXRFfnq2HLBa3G15_Uf5chK_z3ad5jG37G6JeVQQ1A2yR5KXl8TqaftG5N5Et5jTHwAtWWd8KJupRVqX2p7BnWMioHdeLpX2nQdoUSxNXNK1-tmVoN74uV3yw==" rel="nofollow" target="_blank"><strong><u>Click Here</u></strong></a><br><br><strong>September 21 (World Alzheimer’s Day): ProMIS Neurosciences and Nasdaq mark World Alzheimer’s Day at the Nasdaq Tower</strong><br>Location: Nasdaq Tower, New York, NY<br><br><strong>September 29: Roth Healthcare Opportunities Conference</strong><br>Location: New York, NY<br><br>During these conferences, Neil Warma, President &amp; Chief Executive Officer of ProMIS Neurosciences, Dr. Larry Altstiel, Chief Medical Officer, and Carie Pierce, VP, Investor Relations &amp; External Affairs, will discuss the Company’s EpiSelect™ platform, its differentiated approach to developing therapeutics for neurodegenerative diseases driven by toxic misfolded proteins, and PMN310, the Company’s lead candidate in the ongoing PRECISE-AD Phase 1b trial in early Alzheimer’s disease.<br><br>ProMIS reported blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in patients with early AD in July 2026, with 12-month topline data anticipated in early 2027.<br><br>Webcast replays of the upcoming presentations, as well as a replay of the interim data webinar, will be available in the Investors section of the website. <a href="https://www.globenewswire.com/Tracker?data=8g0TB6Gjb7IPuhBxTwLy4OaymGZ3Kx4hbUuNZ0fklYpzAjPa4uRaCUhvBudgL6VGAQ14jksPNlqFzEVgUH33NoeuCpjlJlrqyEozEPC_4UP3C1xWlhH4SsgxQfQY4z3H" rel="nofollow" target="_blank"><u>Click Here</u></a><br><br><strong>About ProMIS Neurosciences Inc.</strong><br><strong><br></strong>ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).<br><br><strong>Investor Relations Contact:</strong><br><strong><br></strong>Carie Pierce, VP, Investor Relations &amp; External Affairs<br><br>IR@promisneurosciences.com</p>               <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/26bec3c9-ac4b-487b-ab90-3b62be29497d"><img src="https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg" border="0" width="150" height="63" alt="Primary Logo"></a></p>
Source: ProMIS Neurosciences Inc.

]]></content:encoded>
                            </item>
                    <item>
                <title><![CDATA[ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.promisneurosciences.com/news-media/press-releases/detail/273/promis-neurosciences-announces-second-quarter-2026</link>
                <pubDate>Thu, 13 Aug 26 16:00:00 -0400</pubDate>
                <guid>https://www.promisneurosciences.com/news-media/press-releases/detail/273/promis-neurosciences-announces-second-quarter-2026</guid>
                                                                                    <content:encoded><![CDATA[

<ul type="disc">
<li style="text-align:left;">&nbsp;<i>Announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Company's Phase 1b trial of PMN310 in patients with early Alzheimer's disease (AD), including zero cases of amyloid-related imaging abnormalities-edema (ARIA-E) across all participants and genotypes, including APOE4 homozygotes.</i>
</li>
<li style="text-align:left;"><i>Observed early, directionally consistent declines in two complementary biomarkers, plasma pTau217 and CSF MTBR-tau243, in a blinded analysis pooling both active- and placebo-treated patients under the trial’s ongoing 3-to-1 randomization.</i></li>
<li style="text-align:left;"><i>The second quarter ended with $53.4 million in cash and short-term investments, which is expected to fund operations through 2027, beyond the Company’s anticipated 12-month topline PRECISE-AD readout expected in the first quarter of 2027.</i></li>
</ul>     <p align="left"><b>Cambridge, Massachusetts, Aug.  13, 2026  (GLOBE NEWSWIRE) -- </b>ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases, today announced its financial results for the quarter ended June 30, 2026, and provided a corporate update.</p>     <p align="left">“The second quarter of 2026 was a pivotal period for ProMIS, as we continued to advance PRECISE-AD while maintaining a strong financial position,” said Neil Warma, President and Chief Executive Officer of ProMIS Neurosciences. “We ended the quarter with $53.4 million in cash and short-term investments, providing runway through 2027, beyond our next major anticipated catalyst.”</p>     <p align="left">“Subsequent to quarter end, on July 28<sup>th</sup>, we announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, our Phase 1b trial of PMN310 in patients with early AD. Across all 136 safety-evaluable participants and APOE genotypes, we observed no cases of ARIA-E. We also observed an early and directionally consistent movement in plasma pTau217 and CSF MTBR-tau243 in the blinded analysis, which pooled active and placebo-treated patients.”</p>     <p align="left">“We believe these data reinforce the thesis behind PMN310: that selectively targeting toxic amyloid-beta oligomers and avoiding plaque may offer a path to amyloid-directed therapy with a significantly improved safety profile, including a substantially reduced ARIA burden, and a potential for improved efficacy. We look forward to the 12-month unblinded topline results from PRECISE-AD, expected in the first quarter of 2027, which will include cognitive outcomes, and we believe will represent an important next step in evaluating PMN310’s potential for patients with early AD.”</p>     <p align="left"><b>Corporate Highlights</b></p>     <p align="left"><b><i>Alzheimer’s Disease (AD) Program (PMN310) — PRECISE-AD Interim Data</i></b></p>     <ul type="disc"><li>PRECISE-AD is a randomized, double-blind, placebo-controlled Phase 1b trial evaluating PMN310 in patients with mild cognitive impairment due to early AD. The trial completed enrollment in December 2025 with 144 subjects across 22 U.S. sites, randomized 3-to-1 to active drug versus placebo across three different dose cohorts (5, 10, and 20 mg/kg), dosed monthly by intravenous infusion over 12 months.</li></ul>     <ul type="disc"><li>The evaluable number of patients in the interim analysis was 136 of the 144 enrolled. The population was genetically and demographically representative: mean age of 73.3 years, 58% female, and 61% carrying at least one APOE4 allele, including 11% APOE4 homozygotes, the population at highest risk of ARIA with plaque-binding antibodies. As of the July 22, 2026 data cutoff date, all 136 safety-evaluable patients had been dosed for at least six months, 78% for at least nine months, and 49% had completed the full 12 months of dosing.</li></ul>     <ul type="disc"><li>Safety: The interim data demonstrated a favorable safety profile across all genotypes, including APOE4 homozygotes. There were no cases of ARIA-E and a 4.4% incidence of total ARIA (all mild and asymptomatic, consisting of only amyloid-related imaging abnormalities -microhemorrhages (ARIA-H)), with no treatment-related serious adverse events and no drug-related discontinuations at the interim.</li></ul>     <ul type="disc"><li>Biomarkers: In the blinded, pooled analysis, plasma pTau217 declined approximately 15% from baseline through Day 169, with roughly 68.5% of patients showing a decline, and CSF MTBR-tau243 declined approximately 13.3%, with approximately 62.5% of patients showing a decline. Both the direction and proportion of patients showing a favorable response are broadly consistent with the trial’s 75% active-drug allocation.</li></ul>     <ul type="disc"><li>The trial remains blinded and ongoing. The Company expects all patients to complete 12-month dosing by the fourth quarter of 2026 and, following database lock and statistical analysis, to report unblinded 12-month topline data, including the full safety dataset, an expanded biomarker panel, and clinical cognitive outcome measures, in the first quarter of 2027.</li></ul>     <p align="left"><b><i>Pipeline Progress and Scientific Presentations</i></b></p>     <ul type="disc"><li>PMN267 (ALS/FTD): The Company’s program targeting misfolded TDP-43 has been humanized in a human IgG1 framework and is progressing through investigational new drug (IND)-enabling studies.</li></ul>     <ul type="disc"><li>PMN442 (Parkinson’s Disease, Dementia with Lewy Bodies, Multiple System Atrophy): The Company’s lead candidate targeting pathogenic alpha-synuclein has been humanized and is advancing toward IND-enabling studies based on its selective binding activity.</li></ul>     <ul type="disc"><li>The Company presented a poster at the 2026 Alzheimer’s Association International Conference (AAIC) highlighting the first human evidence of amyloid-beta oligomer target engagement and removal by PMN310.</li></ul>     <p align="left"><b><i>Corporate and Investor Activities</i></b></p>     <ul type="disc"><li>Mr. Warma presented at multiple investor conferences during the quarter, including the Jefferies Global Healthcare Conference, the Wolfe Research R&amp;D Day focused on Alzheimer’s disease, and the H.C. Wainwright Neuro Perspectives Expert Summit.</li></ul>     <ul type="disc"><li>An additional four research firms initiated coverage of ProMIS during the quarter: Cantor Fitzgerald, Roth Capital, Brookline Capital Markets, and Chardan Capital Markets.</li></ul>     <ul type="disc"><li>ProMIS hosted a live webinar to share the interim blinded data results with two independent key opinion leaders, Dr. Will Mantyh of the University of Minnesota and Dr. Michael Weiner of University of California San Francisco, who offered their perspective on the data and its clinical relevance.</li></ul>     <p align="left"><b><i>Future Activities and Upcoming Milestones</i></b></p>     <ul type="disc"><li>Participation and presentations at multiple investor and medical conferences, including Clinical Trials on AD (CTAD)</li></ul>     <ul type="disc"><li>Presentation of unblinded 12-month topline data from PRECISE-AD, anticipated in the first quarter of 2027.</li></ul>     <p align="left"><b><i>Second Quarter 2026 Financial Highlights</i></b></p>     <ul type="disc"><li>Cash Position: As of June 30, 2026, the Company’s cash and short-term investments were $53.4 million, compared to $6.1 million as of December 31, 2025. The increase primarily reflects $70.1 million in net proceeds received in January 2026 from a private placement financing in which certain of the Company’s own directors and management participated alongside external investors.</li></ul>     <ul type="disc"><li>Cash Runway: Based on the current operating plan, existing cash resources are expected to fund planned operations through 2027, beyond the anticipated 12-month topline readout from PRECISE-AD expected in Q1 2027.</li></ul>     <ul type="disc"><li>Net Loss: For the quarter ended June 30, 2026, the Company reported a net loss of $11.7 million, or $1.28 per share, compared to a net loss of $10.1 million, or $7.26 per share, for the same period in 2025. The improvement in loss per share reflects the increase in weighted-average shares outstanding following the January 2026 financing.</li></ul>     <p align="left"><b>About ProMIS Neurosciences Inc.</b></p>     <p align="left">ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).</p>     <p align="left"><b>About PMN310 and the PRECISE-AD Trial for Alzheimer’s Disease (AD)</b></p>     <p align="left">PMN310, the Company’s lead product candidate for the treatment of AD, is a humanized IgG1 monoclonal antibody designed to selectively target toxic oligomers while avoiding plaque, thereby potentially reducing or eliminating amyloid-related imaging abnormalities (ARIA) liability. Because PMN310 may not be limited by off-target binding or side effects, it could potentially offer an improved efficacy profile over other amyloid-directed antibody therapeutics. PMN310 was granted Fast Track designation by the U.S. Food and Drug Administration in July 2025.</p>     <p align="left">PRECISE-AD (NCT06750432) is a randomized, double-blind, placebo-controlled Phase 1b study evaluating the safety, tolerability, and pharmacokinetics of multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310 in patients with Mild Cognitive Impairment due to AD or mild AD (Stage 3 and Stage 4 AD). PRECISE-AD is the first study to examine the effects of a monoclonal antibody directed solely against Aβ oligomers on biomarkers associated with AD pathology and clinical outcomes. Safety is a primary outcome of the study, with particular emphasis on assessing whether, as a non-plaque binder, PMN310 may have a reduced risk of ARIA. The study is powered to provide 95% confidence for detection of ARIA and is designed to provide meaningful insight into the effects of PMN310 on biomarkers and clinical outcomes.</p>     <p align="left"><b>EpiSelect™ Drug Discovery Engine</b></p>     <p align="left">Toxic misfolded proteins underlie the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). Generation of therapeutic antibodies selectively targeting only disease-misfolded protein isoforms, while sparing normal or irrelevant isoforms of the same protein, has not yet been successfully achieved by conventional immunization strategies. ProMIS Neurosciences has developed a computational platform (EpiSelect™) to identify conformational epitopes that are uniquely exposed on toxic misfolded proteins, which can then be used to generate misfolding-specific antibodies or vaccine formulations.</p>     <p align="left"><b>Forward-Looking Statements</b></p>     <p align="left">This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, “forward-looking information”) within the meaning of applicable securities laws. Statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Company’s PRECISE-AD Phase 1b clinical trial, the interpretation and clinical significance of the blinded six-month interim safety and biomarker data (including ARIA, Ptau217, and MTBR-tau243 findings) described in this release, the expected timing and&nbsp; nature of topline clinical data of PMN310, its mechanism of action and potential benefits, the potential for PMN310 to offer a differentiated efficacy and safety profile relative to plaque-directed antibodies; the Company’s belief that toxic soluble amyloid-beta oligomers are a primary driver of cognitive decline in AD; statements related to the Company’s preclinical programs; and the Company’s expectation that existing cash resources will fund planned operations through 2027. Statements containing forward-looking information are not historical facts but instead represent management’s current expectations, estimates, and projections regarding the future of the business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions, and other factors that may cause actual results, level of activity, performance or achievement to differ materially from those expressed or implied, including, but not limited to, the risk that early or interim results may not be indicative of final or top-line results, the Company’s accumulated deficit, and the expectation for continued losses. Important factors that could cause actual results to differ materially are discussed in the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K and in its subsequent filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p>     <p align="left"><b>Condensed Consolidated Balance Sheets (Unaudited)</b></p>    <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;">
<tbody><tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> &nbsp; </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>June 30, 2026</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>December 31, 2025</b> </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Assets </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> &nbsp; </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> &nbsp; </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Cash </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> $53,429,280 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> $6,116,556 </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Short-term investments </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 33,753 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 33,753 </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Prepaid expenses and other current assets </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 3,230,900 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 3,032,112 </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Total current assets </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$56,693,933</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$9,182,421</b> </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Total assets </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$56,693,933</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$9,182,421</b> </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Liabilities and Shareholders’ Equity </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> &nbsp; </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> &nbsp; </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Accounts payable </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> $1,793,475 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> $2,543,415 </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Accrued liabilities </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 5,424,269 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 7,868,416 </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Total current liabilities </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$7,217,744</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$10,411,831</b> </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Share-based compensation liability </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 77,255 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 29,182 </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Total liabilities </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$7,294,999</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$10,441,013</b> </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Additional paid-in capital </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 200,150,367 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 129,518,812 </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Accumulated other comprehensive loss </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> (371,184) </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> (371,184) </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Accumulated deficit </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> (150,380,249) </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> (130,406,220) </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Total shareholders’ equity (deficit) </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$49,398,934</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$(1,258,592)</b> </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Total liabilities and shareholders’ equity (deficit) </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$56,693,933</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$9,182,421</b> </td>
</tr>
</tbody></table>    <p align="left">&nbsp;<br><b>Condensed Consolidated Statements of Operations (Unaudited)</b></p>    <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;">
<tbody><tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> &nbsp; </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>Three Months Ended June 30, 2026</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>Three Months Ended June 30, 2025</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>Six Months Ended June 30, 2026</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>Six Months Ended June 30, 2025</b> </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Research and development </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> $9,521,793 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> $8,749,784 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> $16,492,799 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> $14,214,034 </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> General and administrative </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 2,744,606 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 1,434,877 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 4,418,497 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 3,430,723 </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Total operating expenses </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$12,266,399</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$10,184,661</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$20,911,296</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$17,644,757</b> </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Loss from operations </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> (12,266,399) </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> (10,184,661) </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> (20,911,296) </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> (17,644,757) </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Other income </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 536,743 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 67,632 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 937,267 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 179,825 </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Net loss </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$(11,729,656)</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$(10,117,029)</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$(19,974,029)</b> </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> <b>$(17,464,932)</b> </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Net loss per share, basic and diluted </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> $(1.28) </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> $(7.26) </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> $(2.54) </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> $(12.53) </td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: middle ; "> Weighted-average outstanding Common Shares, basic and diluted </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 9,142,366 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 1,394,048 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 7,874,562 </td>
<td style="text-align: right ;  vertical-align: middle; vertical-align: middle ; "> 1,394,048 </td>
</tr>
</tbody></table>    <p align="left"><br><b>For Investor Relations, please contact:</b></p>     <p align="left">Carie Pierce</p>     <p align="left">VP, Investor Relations &amp; External Affairs</p>     <p align="left">IR@promisneurosciences.com</p>    <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/26bec3c9-ac4b-487b-ab90-3b62be29497d"><img src="https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg" border="0" width="150" height="63" alt="Primary Logo"></a></p>
Source: ProMIS Neurosciences Inc.

]]></content:encoded>
                            </item>
                    <item>
                <title><![CDATA[ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.promisneurosciences.com/news-media/press-releases/detail/272/promis-neurosciences-to-report-second-quarter-2026</link>
                <pubDate>Mon, 03 Aug 26 16:00:00 -0400</pubDate>
                <guid>https://www.promisneurosciences.com/news-media/press-releases/detail/272/promis-neurosciences-to-report-second-quarter-2026</guid>
                                                                                    <content:encoded><![CDATA[

<p align="left"><em>Company to host investor conference call and webcast at 4:30 p.m. ET.</em></p>     <p align="left"><strong>Cambridge, Massachusetts, Aug.  03, 2026  (GLOBE NEWSWIRE) -- </strong>ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced it will report financial results for the second quarter ended June 30, 2026, and provide corporate updates on August 13, 2026.</p>      <p align="left">The company will host a conference call and webcast on the same day of August 13, 2026 at 4:30 p.m. ET.</p>      <p align="left"><strong><u>Conference Call and Webcast Information:&nbsp;</u></strong></p>   <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;">
<tbody><tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><strong>&nbsp; Date:</strong></td>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">August 13, 2026</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><strong>&nbsp; Time:</strong></td>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">4:30 p.m. Eastern Time</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><strong>&nbsp; Dial-in:</strong></td>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">1-877-407-9208 (U.S. Investors)<br>1-201-493-6784 (International)</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><strong>&nbsp; Conference I.D.:</strong></td>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">13761812</td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; ">
<strong>&nbsp; CallMe</strong><sup><strong>TM</strong></sup><strong>:</strong>
</td>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><a href="https://callme.viavid.com/viavid/?callme=true&amp;passcode=13761812&amp;h=true&amp;info=company-email&amp;r=true&amp;B=6" rel="nofollow" target="_blank"><u>Click Here</u></a></td>
</tr>
<tr>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><strong>&nbsp; Webcast:</strong></td>
<td style="text-align: left ;  vertical-align: middle; vertical-align: top ; "><a href="https://viavid.webcasts.com/starthere.jsp?ei=1770100&amp;tp_key=bee80c12c70" rel="nofollow" target="_blank"><u>Click Here</u></a></td>
</tr>
</tbody></table>    <p align="left">A replay of the webcast will be available in the Investors section of the ProMIS website following the completion of the call.</p>      <p align="left"><strong>About ProMIS Neurosciences Inc.</strong><br>ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company's proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative diseases, including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson's disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).</p>       <p align="left"><strong>For further information:</strong><br>Visit us at www.promisneurosciences.com</p>       <p align="left"><strong>Media Contact</strong><br>Maggie Whitney<br>LifeSci Communications<br>mwhitney@lifescicomms.com</p>       <p align="left"><strong>Investor Relations Contact</strong><br>Carie Pierce<br>VP Investor Relations &amp; External Affairs<br>IR@ProMISNeurosciences.com</p>    <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/26bec3c9-ac4b-487b-ab90-3b62be29497d"><img src="https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg" border="0" width="150" height="63" alt="Primary Logo"></a></p>
Source: ProMIS Neurosciences Inc.

]]></content:encoded>
                            </item>
                    <item>
                <title><![CDATA[ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.promisneurosciences.com/news-media/press-releases/detail/271/promis-neurosciences-reports-positive-blinded-six-month</link>
                <pubDate>Tue, 28 Jul 26 06:00:00 -0400</pubDate>
                <guid>https://www.promisneurosciences.com/news-media/press-releases/detail/271/promis-neurosciences-reports-positive-blinded-six-month</guid>
                                                                                    <content:encoded><![CDATA[

<p align="left" style="padding-left:40px;"><em>No ARIA-E observed across all genotypes, including APOE4 homozygotes</em></p>     <p align="left" style="padding-left:40px;"><em>ARIA-H tracking background rates</em></p>     <p align="left" style="padding-left:40px;"><em>Early biomarker movement consistent with target engagement</em></p>     <p align="left" style="padding-left:40px;"><em>12-month topline results expected in Q1 2027</em></p>     <p align="left">Cambridge, Massachusetts, July  28, 2026  (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biopharmaceutical company developing therapeutics that selectively target toxic misfolded proteins in neurodegenerative diseases, today announced positive blinded six-month interim safety and biomarker results from PRECISE-AD, the Phase 1b trial of its lead drug candidate, PMN310, in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease (AD).<br><br>In the blinded interim analysis evaluating 136 AD patients, PMN310 was observed to have a favorable safety profile across all genotypes, with no cases of amyloid-related imaging abnormalities-edema (ARIA-E) reported as of the data cutoff date, and early, directionally consistent movement in disease-relevant biomarkers potentially reflective of the randomization pattern. The trial remains blinded and ongoing with topline 12-month results expected in the first quarter of 2027.</p>      <p align="left"><strong>Interim Highlights</strong></p>     <ul type="disc">
<li>
<strong>Favorable safety profile across all genotypes:&nbsp;</strong>No ARIA-E and 4.4% total ARIA (all mild and asymptomatic, consisting of only amyloid-related imaging abnormalities-microhemorrhages (ARIA-H)), with no treatment-related serious adverse events and no drug-related discontinuations at the interim.<br><br>
</li>
<li>
<strong>Same profile in high-risk APOE4 carriers:&nbsp;</strong>No ARIA-E observed in any genotype in a population that included 61% APOE4 carriers, of which 11% were homozygotes, a group underserved by approved amyloid-directed therapies.<br><br>
</li>
<li>
<strong>Early biomarker movement consistent with target engagement:&nbsp;</strong>On a blinded basis, a majority of patients showed reductions in disease-relevant biomarkers against expected increases in natural-history trajectories: 68.5% of patients had a decline from baseline (change ≤ 0) in plasma pTau217 and 62.5% had a decline in CSF MTBR-tau243, consistent with a potential beneficial drug effect and potentially reflective of the trial’s 3:1 active-to-placebo randomization. These are blinded interim biomarker observations, meaning treatment allocations between drug and placebo groups are not known at this time. These observed biomarker trends are not a determination of efficacy, and trends in biomarkers may not ultimately be reflective of clinical effects.<br><br>
</li>
<li>
<strong>Differentiated, oligomer-selective mechanism:&nbsp;</strong>PMN310 is designed to selectively bind toxic amyloid-beta oligomers while avoiding plaque, a mechanism intended to decouple potential efficacy from ARIA risk.<br><br>
</li>
<li>
<strong>Clear path forward:&nbsp;</strong>Unblinded 12-month topline data expected Q1 2027, including efficacy data.</li>
</ul>     <p align="left" style="padding-left:40px;">“These interim data reinforce our central thesis: by selectively targeting toxic oligomers, PMN310 has the potential to deliver the benefits of amyloid-directed therapy without the ARIA burden that has constrained this class of drugs,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. “The absence of ARIA-E, an overall favorable safety profile, and early biomarker movement together align with our expectations based on our prior studies. We look forward to our 12-month topline readout in the first quarter of 2027.”<br><br>Dr. Will Mantyh, a behavioral neurologist at the University of Minnesota, said, “In real-world practice, ARIA risk is the central prescribing barrier: clinicians, patients, and health systems must contend with the issues of safety monitoring, identification, and sometimes emergent neurological&nbsp;treatment of ARIA.&nbsp;A profile with low incidence of total ARIA, including no ARIA-E,&nbsp;would be a game-changer. Just as importantly, plasma pTau217 and CSF MTBR-tau243 are among the most informative fluid biomarkers we have for tracking Alzheimer’s biology; seeing early, coherent movement in both is highly encouraging&nbsp;before a definitive readout.”</p>       <p align="left"><br>ProMIS will host a live webinar today to discuss these results.&nbsp;<br><br></p>     <p align="left"><strong>Webinar Details</strong></p>     <p align="left"><strong>Date: </strong>July 28, 2026</p>     <p align="left"><strong>Time: </strong>8:00–9:00 a.m. ET</p>     <p align="left"><strong>Speakers (ProMIS): </strong>Neil Warma, Chief Executive Officer, and Dr. Larry Altstiel, Chief Medical Officer</p>     <p align="left"><strong>Featured Key Opinion Leaders: </strong>Dr. Will Mantyh and Dr. Michael Weiner</p>     <p align="left"><strong>Registration: </strong><a href="https://www.globenewswire.com/Tracker?data=cSGjdl9rLFpMhBjTYkzADOTNbcUuzmXR6Axr8MUayti1ie-r_boC5aQIDd8mJvlQt8AZZ4Q0oSpXPsLJj0QknRATG1hfqP0GS-b9kOAhtUsdtFJDbONYMIhAqAp-IXjk-U2vD7UfJrAKtThS_x__Pw==" rel="nofollow" target="_blank">https://lifescievents.com/event/it38tlq/</a></p>     <p align="left">&nbsp;</p>     <p align="left"><strong>About PMN310 and the PRECISE-AD Trial for Alzheimer’s Disease (AD)</strong></p>     <p align="left">PMN310, ProMIS’ lead product candidate for the treatment of AD, is a humanized IgG1 monoclonal antibody designed to selectively target only the toxic oligomers of amyloid-beta (AβOs), believed to be among the earliest and most damaging drivers of Alzheimer’s disease, while avoiding binding to amyloid plaques and vascular deposits. This selectivity may reduce or eliminate the risk of amyloid-related imaging abnormalities (ARIA), including brain swelling (ARIA-E) and microhemorrhages (ARIA-H), which are commonly associated with plaque-binding antibodies. PMN310 was granted Fast Track Designation by the U.S. Food and Drug Administration in July 2025.<br><br>Based on encouraging results from a Phase 1a trial (NCT06105528) in healthy volunteers, ProMIS initiated the PRECISE-AD Phase 1b trial to evaluate PMN310 in patients with mild cognitive impairment due to AD or mild AD. PRECISE-AD (NCT06750432) is a randomized, double-blind, placebo-controlled study evaluating the safety, tolerability, and pharmacokinetics of multiple ascending doses (5, 10, and 20 mg/kg) of intravenous PMN310. The study has completed enrollment of 144 participants across the three dosing cohorts who are being treated for twelve months. It is designed to provide meaningful insight into the effects of PMN310 on biomarkers and clinical outcomes.</p>      <p align="left"><strong>About ProMIS Neurosciences Inc.</strong></p>     <p align="left">ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).</p>     <p align="left"><strong>Forward-Looking Statements</strong></p>     <p align="left">This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, “forward-looking information”) within the meaning of applicable securities laws. Statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Company’s PRECISE-AD Phase 1b clinical trial, the interpretation and significance of the blinded six-month interim safety and biomarker data (including ARIA, pTau217, and MTBR-tau243 findings) described in this release, target engagement, the expected timing and nature of topline clinical data of PMN310, its mechanism of action and potential benefits, and the Company’s development plans. Statements containing forward-looking information are not historical facts but instead represent management’s current expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that early or interim results may not be indicative of future results and that blinded, pooled data may not reflect the effect of PMN310 once unblinded. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the “Risk Factors” section of the Company’s most recently filed Annual Report on Form 10-K for the year ended December 31, 2025 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p>     <p align="left"><strong>For further information:</strong></p>     <p align="left">Visit us at <a href="https://www.globenewswire.com/Tracker?data=wWG9NTQVLK23HR0c_MolVJJaPC_W3lGlCJWUYpYN1Ex7oqGP2VsrTtRfhqGRW3NNfIYB9VFmE03kh4CGRT4U9hjWK9IcWJrJspQsei1e19MdhFjY4aeOQgwiob2qZ_gq" rel="nofollow" target="_blank">www.promisneurosciences.com</a></p>      <p align="left"><strong>Media Contact</strong><br>Maggie Whitney<br>LifeSci Communications<br><a href="https://www.globenewswire.com/Tracker?data=50Z2V7S9p-mQu1MQWy_uEQH8esKRUM57I_6g-h6Aq8d5DX3DTixStmrRG0yKN7ciUTqlb4S4UqhweDXwxGkIU9yGScFy6gsKmOfnhmZXdBVva4bFuZvnURc8c4nP91-W" rel="nofollow" target="_blank">mwhitney@lifescicomms.com</a></p>      <p align="left"><strong>Investor Relations Contact</strong><br>Carie Pierce<br>VP Investor Relations &amp; External Affairs<br><a href="https://www.globenewswire.com/Tracker?data=FpCtd8vFQGBsdfGfeGdJ-w-HtoeDBoGPp4c19HqQAQTYiyuJjFTx-DcU4gBZufR2bxE91MmMViY8zXmdNg3yqCLQKNZq-mpIuGlw5q0BmDmECvnnp-kXjHS6XEAqgIFS" rel="nofollow" target="_blank">IR@ProMISNeurosciences.com</a></p>   <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/26bec3c9-ac4b-487b-ab90-3b62be29497d"><img src="https://ml.globenewswire.com/media/26bec3c9-ac4b-487b-ab90-3b62be29497d/small/promis-jpg.jpg" border="0" width="150" height="63" alt="Primary Logo"></a></p>
Source: ProMIS Neurosciences Inc.

]]></content:encoded>
                            </item>
            </channel>
</rss>